Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 1017-1024

  Chau, I ^a   Allen, M ^a   Cunningham, D ^a   Tait, D ^b   Brown, G ^b   Hill, M ^a   Sumpter, K ^a   Rhodes, A ^b   Wotherspoon, A ^b   Norman, A R ^b   Hill, A ^a   Massey, A ^a   Prior, Y ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Circumferential resection margin; Fluorouracil; Magnetic resonance imaging; Neoadjuvant chemotherapy; Radiotherapy

Indexed keywords

FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; FEMALE; HUMAN; HUMAN TISSUE; INFUSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS PAIN SYNDROME; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CARCINOMA; RECTUM HEMORRHAGE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; POSTOPERATIVE COMPLICATIONS; RECTAL NEOPLASMS;

EID: 0038030757     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600822     Document Type: Article

References (50)

1. National Cancer Institute-Common Toxicity Criteria (1998) National Cancer Institute Bethesda http://ctep.cancer.gov/reporting/ctc.html
2. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P (1994) Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344: 707-711
3. Aschele C, Friso ML, Pucciarelli S, Sartor L, Lonard S, De Salvo G, Fabris G, Da Dalt G, Ranzato R, Bruttocao A, Neri D, Finco C, Monfardini S (2002) A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc Am Soc Clin Oncol 21: 132a
4. Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, von Meyenfeldt MF, Baeten CG, van Engelshoven JM (2001) Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357: 497-504
5. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, Abbott CR, Scott N, Finan PJ, Johnston D, Quirke P (2002) Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 235: 449-457
6. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759-1766
7. Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, Chaillard G, Horiot JC (2000) Preoperative racliochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 46: 323-327
8. Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP, Bourne MW, Williams GT (1999) Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 211: 215-222
9. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284: 1008-1015
10. Chan AK, Wong AO, Langevin J, Jenken D, Heine J, Buie D, Johnson DR (2000) Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II close escalation study. Int J Radiat Oncol Biol Phys 48: 843-856
11. Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358: 1291-1304
12. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418
13. Dahlberg M, Glimelius B, Pahlman L (1999) Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg 229: 493-497
14. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louver C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
15. Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, Frings S (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20: 3983-3991
16. Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, Gerard JP (2001) Addition of oxaliplatin to continuous fuorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 19: 2433-2438
17. Gerard JP, Chapet O, Romestaing P, Mornex F, Coquard R, Barber N, Atlan D, Freyer G (2002) Oxaliplatin, fuorouracil, I-leucovorin and radiotherapy (FolfoR 2) as preoperative treatment of advanced rectal cancer: the Lyon R0-04 phase II trial. Proc Am Soc Clin Oncol 21: 146a
18. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fuorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147
19. Glimelius B (2001) Chemoradiotherapy for rectal cancer-is there an optimal combination? Ann Oncol 12: 1039-1045
20. Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanthan RK, Williamson SK, Findlay, BP (2002) N9741: oxaliplatin (oxal) or CPT-11+5-fluorouracil (5FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21: 128a
21. Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, Cohen AM, Minsky BD (2001) Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 49: 987-995
22. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen HC, Van de Velde CJ (1999) Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 25: 368-374
23. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 133: 894-899
24. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 194: 131-135
25. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J (1999) Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44: 1027-1038
26. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, Van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638-646
27. Kapiteijn E, Putter H, Van de Velde CJ (2002) Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 89: 1142-1149
28. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
29. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH (2002) Preoperative chemoradiation using oral capecitablne in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54: 403-408
30. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130-3136
31. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
32. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Van de Velde CJ, van Krieken JH (2002) Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 26: 350-357
33. Nesbakken A, Nygaard K, Westerheim O, Mala T, Lunde OC (2002) Local recurrence after mesorectal excision for rectal cancer. Eur J Surg Oncol 28: 126-134
34. Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS (2001) Neoadiuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg 233: 778-785
35. Quirke P, Durdey P, Dixon MF, Williams NS (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2: 996-999
36. Rodel C, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W, Sauer R (2000) Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. Strahlenther Onkol 176: 161-167
37. Roh M, Petrelli N, Wieand S, Colangelo L, Smith R, Mamounas E, Hyams D, Wolmark N (2001) Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 20: 123a
38. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004
39. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
40. Russello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A (1989) Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 25: 571-572
41. Sauer R, Fietkau R, Wittekind C, Martus P, Rodel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H, Hess C, Raab R (2001) Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 177: 173-181
42. Sebag-Montefiore D, Glynn RJ, Falk S, Maughan T, Meadows HM (2002) Preoperative radiation and oxaliplatin in combination with 5-fluorouracil and low-dose leucovorin in locally advanced rectal cancer. Proc Am Soc Clin Oncol 21: 146a
43. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336: 980-987
44. Taberno JM, Butts CA, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, Figer A, Schoeffski P, Grossmann A, Sobrero A, Twelves C, Van Cutsem E (2002) Capecitabine and oxaliplatin in combination as first line therapy for patients with metastatic colorectal cancer: results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 21: 133a
45. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M (2002) A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 13: 1568-1575
46. Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M (2001) Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys 51: 371-383
47. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F, Cosimelli M (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53: 664-674
48. Van de Velde CJ (2002) Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analyses in relation to quality control in a randomized trial. Proc Am Soc Clin Oncol 21: 127a
49. Videtic GM, Fisher BJ, Perera FE, Bauman GS, Kocha WI, Taylor M, Vincent MD, Plewes EA, Engel CJ, Stitt LW (1998) Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 42: 319-324
50. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, Soreide O (2002) Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 89: 327-334